Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically-based pharmacokinetic modeling.

Yeung, Cindy H T; Beers, Jessica L; Jackson, Klarissa D; Edginton, Andrea N

Yeung, Cindy H T; Beers, Jessica L; Jackson, Klarissa D; Edginton, Andrea N.

Afiliación

Yeung CHT; School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.
Beers JL; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, California, USA.
Jackson KD; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, California, USA.
Edginton AN; School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.

CPT Pharmacometrics Syst Pharmacol ; 12(3): 320-332, 2023 03.

Article en En | MEDLINE | ID: mdl-36540909

Asunto(s)

Cannabidiol; Preescolar; Adulto; Humanos; Niño; Cannabidiol/farmacocinética; Interacciones Farmacológicas; Fluconazol; Rifampin; Itraconazol

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cannabidiol Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Child / Child, preschool / Humans Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google